A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Agulnik, M
  • Cohen, EE
  • Cohen, RB
  • Chen, EX
  • Hotte, Sebastien
  • Winquist, E
  • Laurie, S
  • Hayes, DN
  • Dancey, JE
  • Siu, LL

publication date

  • June 20, 2006